导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.17% | 2277/4773 |
| 近一周 | -1.41% | 2495/5467 |
| 近一月 | -4.94% | 2043/5421 |
| 近一季 | -7.10% | 2236/5238 |
| 近半年 | -0.87% | 1807/4931 |
| 近一年 | 2.13% | 2124/4400 |
| 近两年 | 48.31% | 1531/2954 |
| 近三年 | 29.34% | 1095/2253 |
| 成立以来 | 63.87% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.09% 3031/4961 |
13.00% 2078/5312 |
- - |
- - |
| 2025 | 19.76% 2186/4813 |
-0.81% 2420/3635 |
1.84% 2094/4076 |
17.86% 2416/4524 |
0.59% 1915/4813 |
| 2024 | 15.01% 977/3463 |
2.39% 783/2808 |
-1.44% 1064/3014 |
15.58% 1679/3129 |
-1.40% 1684/3463 |
| 2023 | -9.94% 1250/2656 |
3.52% 1176/2280 |
-4.75% 1279/2385 |
-2.96% 804/2515 |
-5.88% 1539/2655 |
| 2022 | -17.56% 604/2207 |
-13.67% 807/1919 |
7.23% 506/2016 |
-12.01% 629/2113 |
1.21% 1345/2208 |
| 2021 | 4.00% 593/1822 |
-2.61% 678/1255 |
7.97% 655/1330 |
-3.09% 612/1466 |
2.06% 710/1822 |
| 2020 | 31.37% 503/1250 |
-7.16% 526/1028 |
14.23% 562/1067 |
10.26% 569/1164 |
12.36% 474/1184 |
| 2019 | 33.62% 429/1092 |
24.53% 508/739 |
-0.36% 249/788 |
0.70% 480/850 |
6.95% 511/918 |
| 2018 | - - |
- - |
- - |
0.20% 158/660 |
-11.45% 295/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 招商MSCI中国A股国际ETF联接C VS. 长安沪深300非周期A(740101) |